OBJECTIVES: The purpose of the study was to define the extent and nature of cardiac resynchronization therapy (CRT) device usage outside consensus guidelines using national data. BACKGROUND: Recent literature has shown that the application of CRT in clinical practice frequently does not adhere to evidence-based consensus guidelines. Factors underlying these practices have not been fully explored. METHODS: From the National Cardiovascular Data Registry's Implantable Cardiac-Defibrillator Registry, we defined a cohort of 45,392 cardiac resynchronization therapy-defibrillator (CRT-D) implants between January 2006 and June 2008 with a primary prevention indication. We defined "off-label" implants as those in which the ejection fraction was >35%, the New York Heart Association functional class was below III, or the QRS interval duration was <120 ms in the absence of a documented need for ventricular pacing. The relationships between patient, implanting physician, and hospital characteristics with off-label use were explored with multivariable hierarchical logistic regression models. RESULTS: Overall, 23.7% of devices were placed without meeting all 3 implant criteria, most often due to New York Heart Association functional class below III (13.1% of implants) or QRS interval duration <120 ms (12.0%). Atrial fibrillation/flutter, previous percutaneous coronary intervention, and the performance of an electrophysiology study before implant were independently associated with increased odds of off-label use, whereas diabetes mellitus, increasing age, and female sex were associated with decreased odds. Physician training and insurance payer were weakly associated with the likelihood of off-label use. CONCLUSIONS: Nearly 1 in 4 patients receiving CRT devices in the study time frame did not meet guideline-based indications. Given the evolving evidence base supporting the use of CRT, these practices require careful scrutiny. Copyright (c) 2010 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
OBJECTIVES: The purpose of the study was to define the extent and nature of cardiac resynchronization therapy (CRT) device usage outside consensus guidelines using national data. BACKGROUND: Recent literature has shown that the application of CRT in clinical practice frequently does not adhere to evidence-based consensus guidelines. Factors underlying these practices have not been fully explored. METHODS: From the National Cardiovascular Data Registry's Implantable Cardiac-Defibrillator Registry, we defined a cohort of 45,392 cardiac resynchronization therapy-defibrillator (CRT-D) implants between January 2006 and June 2008 with a primary prevention indication. We defined "off-label" implants as those in which the ejection fraction was >35%, the New York Heart Association functional class was below III, or the QRS interval duration was <120 ms in the absence of a documented need for ventricular pacing. The relationships between patient, implanting physician, and hospital characteristics with off-label use were explored with multivariable hierarchical logistic regression models. RESULTS: Overall, 23.7% of devices were placed without meeting all 3 implant criteria, most often due to New York Heart Association functional class below III (13.1% of implants) or QRS interval duration <120 ms (12.0%). Atrial fibrillation/flutter, previous percutaneous coronary intervention, and the performance of an electrophysiology study before implant were independently associated with increased odds of off-label use, whereas diabetes mellitus, increasing age, and female sex were associated with decreased odds. Physician training and insurance payer were weakly associated with the likelihood of off-label use. CONCLUSIONS: Nearly 1 in 4 patients receiving CRT devices in the study time frame did not meet guideline-based indications. Given the evolving evidence base supporting the use of CRT, these practices require careful scrutiny. Copyright (c) 2010 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
Authors: Douglas S Lee; Andrew D Krahn; Jeffrey S Healey; David Birnie; Eugene Crystal; Paul Dorian; Christopher S Simpson; Yaariv Khaykin; Douglas Cameron; Amir Janmohamed; Raymond Yee; Peter C Austin; Zhongliang Chen; Judy Hardy; Jack V Tu Journal: J Am Coll Cardiol Date: 2010-02-23 Impact factor: 24.094
Authors: Mariell Jessup; William T Abraham; Donald E Casey; Arthur M Feldman; Gary S Francis; Theodore G Ganiats; Marvin A Konstam; Donna M Mancini; Peter S Rahko; Marc A Silver; Lynne Warner Stevenson; Clyde W Yancy Journal: Circulation Date: 2009-03-26 Impact factor: 29.690
Authors: Eugene S Chung; Angel R Leon; Luigi Tavazzi; Jing-Ping Sun; Petros Nihoyannopoulos; John Merlino; William T Abraham; Stefano Ghio; Christophe Leclercq; Jeroen J Bax; Cheuk-Man Yu; John Gorcsan; Martin St John Sutton; Johan De Sutter; Jaime Murillo Journal: Circulation Date: 2008-05-05 Impact factor: 29.690
Authors: Jeptha P Curtis; Jeffrey J Luebbert; Yongfei Wang; Saif S Rathore; Jersey Chen; Paul A Heidenreich; Stephen C Hammill; Rachel I Lampert; Harlan M Krumholz Journal: JAMA Date: 2009-04-22 Impact factor: 56.272
Authors: Martin St John Sutton; Stefano Ghio; Ted Plappert; Luigi Tavazzi; Laura Scelsi; Claude Daubert; William T Abraham; Michael R Gold; Christian Hassager; John M Herre; Cecilia Linde Journal: Circulation Date: 2009-10-26 Impact factor: 29.690
Authors: Claude Daubert; Michael R Gold; William T Abraham; Stefano Ghio; Christian Hassager; Grahame Goode; Tamás Szili-Török; Cecilia Linde Journal: J Am Coll Cardiol Date: 2009-10-01 Impact factor: 24.094
Authors: Sana M Al-Khatib; Melissa A Greiner; Eric D Peterson; Adrian F Hernandez; Kevin A Schulman; Lesley H Curtis Journal: Circ Arrhythm Electrophysiol Date: 2008-10
Authors: Arthur J Moss; W Jackson Hall; David S Cannom; Helmut Klein; Mary W Brown; James P Daubert; N A Mark Estes; Elyse Foster; Henry Greenberg; Steven L Higgins; Marc A Pfeffer; Scott D Solomon; David Wilber; Wojciech Zareba Journal: N Engl J Med Date: 2009-09-01 Impact factor: 91.245
Authors: Preston M Schneider; Cara N Pellegrini; Yongfei Wang; Adam S Fein; Matthew R Reynolds; Jeptha P Curtis; Frederick A Masoudi; Paul D Varosy Journal: Am J Cardiol Date: 2014-04-01 Impact factor: 2.778
Authors: John A Dodson; Rachel Lampert; Yongfei Wang; Stephen C Hammill; Paul Varosy; Jeptha P Curtis Journal: Circulation Date: 2013-11-05 Impact factor: 29.690
Authors: Sanjeev P Bhavnani; Craig I Coleman; Danette Guertin; Ravi K Yarlagadda; Christopher A Clyne; Jeffrey Kluger Journal: Ann Noninvasive Electrocardiol Date: 2013-05-03 Impact factor: 1.468
Authors: Daniel B Kramer; Kevin F Kennedy; John A Spertus; Sharon-Lise Normand; Peter A Noseworthy; Alfred E Buxton; Mark E Josephson; Peter J Zimetbaum; Susan L Mitchell; Matthew R Reynolds Journal: Heart Rhythm Date: 2014-02 Impact factor: 6.343
Authors: Daniel B Kramer; Kevin F Kennedy; Peter A Noseworthy; Alfred E Buxton; Mark E Josephson; Sharon-Lise Normand; John A Spertus; Peter J Zimetbaum; Matthew R Reynolds; Susan L Mitchell Journal: Circ Cardiovasc Qual Outcomes Date: 2013-06-11